ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DYN Dyne Therapeutics Inc

33.30
-0.39 (-1.16%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dyne Therapeutics Inc NASDAQ:DYN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.39 -1.16% 33.30 31.40 40.26 33.40 32.64 33.00 579,554 01:00:00

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

02/01/2024 9:05pm

GlobeNewswire Inc.


Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Dyne Therapeutics Charts.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.

Dyne’s leadership team will be joined by two leading neuromuscular disease experts: Valeria A. Sansone, M.D., Ph.D., and Perry Shieh, M.D., Ph.D. Dr. Sansone is the Clinical and Scientific Director at the Clinical Center NeMO in Milan, Professor of Neurology, University of Milan, and a principal investigator for the ACHIEVE trial. Dr. Shieh is Professor of Neurology and Pediatrics at the David Geffen School of Medicine at UCLA and a Neurologist at the Ronald Reagan UCLA Medical Center in Los Angeles, and a principal investigator for the DELIVER trial. The program will feature presentations and Q&A.

The live event webcast will be available in the Events & Presentations page of the Investors & Media section of Dyne’s website and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com, and follow us on X, LinkedIn and Facebook.

Contacts:

InvestorsAmy Reillyareilly@dyne-tx.com 857-341-1203

MediaStacy Nartkersnartker@dyne-tx.com781-317-1938

1 Year Dyne Therapeutics Chart

1 Year Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart

1 Month Dyne Therapeutics Chart

Your Recent History

Delayed Upgrade Clock